RxDoctor Payments Data

Josh Lopez

Family · Elgin, ILNPI 1184166001

Payments from drug & device makers

$10,130in general payments, 2019–2025

Across 601 payments — averaging $16.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$5K
  • Gilead$2K
  • Johnson & Johnson$924
  • Napo Pharmaceuticals Inc$525
  • EMD Serono, Inc.$327
  • AbbVie$274
  • plus $385 from 4 others

What the payments were for

  • Speaking & faculty fees$841%
  • Food & beverage$10,01799%
  • Education$280%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,130 in reported general payments places this provider in the 95th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$15,300
Medicare patients
50
Services billed
159

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala260$1,093,116
DovatoDolutegravir Sodium/Lamivudine253$799,338
JulucaDolutegravir/Rilpivirine155$556,358
RukobiaFostemsavir Tromethamine12$107,451
DescovyEmtricitabine/Tenofov Alafenam41$94,158
TivicayDolutegravir Sodium39$89,139
OdefseyEmtricitab/Rilpiviri/Tenof Ala25$87,670
CabenuvaCabotegravir/Rilpivirine12$85,269
OzempicSemaglutide61$65,284
GenvoyaElviteg/Cob/Emtri/Tenof Alafen11$41,593
JardianceEmpagliflozin35$34,490
JanuviaSitagliptin Phosphate46$29,877
PifeltroDoravirine17$29,858
PrezcobixDarunavir/Cobicistat11$26,626
JanumetSitagliptin Phos/Metformin Hcl25$14,885

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Juluca, Rukobia, Tivicay, Cabenuva$5,461$1,637,555471 claims
GileadBiktarvy, Descovy, Genvoya$2,233$1,228,867312 claims
MerckJanuvia, Pifeltro, Janumet$173$74,61988 claims
Johnson & JohnsonPrezcobix$924$26,62611 claims
Lilly USA, LLCTrulicity, Olanzapine$119$14,70332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,941 family providers in Illinois.

Other family in Elgin

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →